Additionally, ibrutinib diminishes cytokine production, PD-L1 expression, and motility of MDSCs and other myeloid cells, which consequently affects tumor microenvironment regulation and has been linked to decreased tumor vasculature density [4]. Here, CD274 is linked to neoplasm.